C-reactive protein levels are not associated with increased risk for colorectal cancer in women

Annals of Internal Medicine

Volumn 142, Issue 6, 2005, Pages

  Zhang, Shumin M ^a   Buring, Julie E ^a   Lee, I Min ^a   Cook, Nancy R ^a   Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; C REACTIVE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; BIOLOGICAL MARKER;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENTERITIS; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEDICAL RECORD; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; SELF REPORT; SMOKING; ADENOCARCINOMA; BLOOD; COLORECTAL TUMOR; METABOLISM; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL;

ADENOCARCINOMA; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 14844355637     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-142-6-200503150-00008     Document Type: Article

References (43)

1. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-9. [PMID: 12551853]
2. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291:585-90. [PMID: 14762037]
3. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18 Suppl 2:1-5. [PMID: 12950413]
4. Panes J. Inflammatory bowel disease: pathogenesis and targets for therapeutic interventions. Acta Physiol Scand. 2001;173:159-65. [PMID: 11678739]
5. Baron JA. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res. 2003;37:1-24. [PMID: 12795046]
6. Durdey P, Williams NS, Brown DA. Serum carcinoembryonic antigen and acute phase reactant proteins in the pre-operative detection of fixation of colorectal tumours. Br J Surg. 1984;71:881-4. [PMID: 6498459]
7. Mercer DW, Talamo TS. Multiple markers of malignancy in sera of patients with colorectal carcinoma: preliminary clinical studies. Clin Chem. 1985;31:1824-8. [PMID: 2414037]
8. Stamatiadis AP, St Toumanidou M, Vyssoulis GP, Manouras AJ, Apostolidis NS. Value of serum acute-phase reactant proteins and carcinoembryonic antigen in the preoperative staging of colorectal cancer. A multivariate analysis. Cancer. 1990;65:2055-7. [PMID: 1695546]
9. Stamatiadis AP, Manouras AJ, Triantos GN, Katergiannakis VA, Apostolidis NS. Combination of serum carcino-embryonic antigen and C-reactive protein-a useful test in preoperative staging of colorectal cancer. Eur J Surg Oncol. 1992;18:41-3. [PMID: 1737592]
10. Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg. 1998;176:335-8. [PMID: 9817250]
11. Huls G, Koornstra JJ, Kleibeuker JH. Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. Lancet. 2003;362: 230-2. [PMID: 12885487]
12. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-54. [PMID: 9971870]
13. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-7. [PMID: 12490959]
14. Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JE. Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med. 2000;9:19-27. [PMID: 10718501]
15. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-65. [PMID: 12432042]
16. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511. [PMID: 12551878]
17. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation. 1999;100:713-6. [PMID: 10449692]
18. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation. 1999;100:717-22. [PMID: 10449693]
19. van Baal WM, Kenemans P, van der Mooren MJ, Kessel H, Emeis JJ, Stehouwer CD. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost. 1999;81:925-8. [PMID: 10404769]
20. Du Clos TW. Function of C-reactive protein. Ann Med. 2000;32:274-8. [PMID: 10852144]
21. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002;46:3151-8. [PMID: 12483718]
22. Yüceyar S, Ertük S, Dirican A, Cengiz A, Saner H. The role of acute-phase reactant proteins, carcinoembryonic antigen and CA 19-9 as a marker in the preoperative staging of colorectal cancen a prospective clinical study. Int Surg. 1996;81:136-9. [PMID: 8912078]
23. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19:972-8. [PMID: 10195925]
24. McMillan DC, Wotherspoon HA, Fearon KC, Sturgeon C, Cooke TG, McArdle CS. A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am J Surg. 1995;170: 319-22. [PMID: 7573721]
25. Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer. 1999;85:2526-31. [PMID: 10375098]
26. Belluco C, Nitti D, Frantz M, Toppan P, Basso D, Plebani M, et al. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol. 2000;7:133-8. [PMID: 10761792]
27. Nielsen HJ, Christensen IJ, Soørensen S, Moesgaard F, Brunner N. Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol. 2000;7:617-23. [PMID: 11005561]
28. Wigmore SJ, McMahon AJ, Sturgeon CM, Fearon KC. Acute-phase protein response, survival and tumour recurrence in patients with colorectal cancer. Br J Surg. 2001;88:255-60. [PMID: 11167877]
29. McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer. 2001;41:64-9. [PMID: 12094630]
30. Chung YC, Chang YF. Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. Eur J Gastroenterol Hepatol. 2003;15:369-73. [PMID: 12655256]
31. Chung YC, Chang YF. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol. 2003;83:222-6. [PMID: 12884234]
32. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg. 2003; 90:215-9. [PMID: 12555298]
33. Komoda H, Tanaka Y, Honda M, Matsuo Y, Hazama K, Takao T. Interleukin-6 levels in colorectal cancer tissues. World J Surg. 1998;22:895-8. [PMID: 9673566]
34. Pasche B, Serhan CN. Is C-reactive protein an inflammation opsonin that signals colon cancer risk? [Editorial] JAMA. 2004;291:623-4. [PMID: 14762043]
35. Vatay A, Bene L, Kovacs A, Prohaszka Z, Szalai C, Romics L, et al. Relationship between the tumor necrosis factor alpha polymorphism and the serum C-reactive protein levels in inflammatory bowel disease. Immunogenetics. 2003; 55:247-52. [PMID: 12811429]
36. Ries LA, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, et al, eds. SEER Cancer Statistics Review, 1975-2001. Bethesda, MD: National Cancer Institute. Accessed at http://seer.cancer.gov/csr/1975_2001 on 7 November 2004.
37. Breen N, Wagener DK, Brown ML, Daws WW, Ballard-Barbash R. Progress in cancer screening over a decade: results of cancer screening from the 1987, 1992, and 1998 National Health Interview Surveys. J Natl Cancer Inst. 2001;93:1704-13. [PMID: 11717331]
38. Demissie K, Oluwole OO, Balasubramanian BA, Osinubi OO, August D, Rhoads GG. Racial differences in the treatment of colorectal cancer: a comparison of surgical and radiation therapy between Whites and Blacks. Ann Epidemiol. 2004;14:215-21. [PMID: 15036226]
39. Crespo CJ, Smit E, Snelling A, Sempos CT, Andersen RE. Hormone replacement therapy and its relationship to lipid and glucose metabolism in diabetic and nondiabetic postmenopausal women: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care. 2002; 25:1675-80. [PMID: 12351460]
40. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem. 2001;47:444-50. [PMID: 11238295]
41. Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem. 2001;47:426-30. [PMID: 11238292]
42. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-34. [PMID: 11466099]
43. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290:2945-51. [PMID: 14665655]